Speaking at AAPS PharmSci 360, Dr Stephanie Johnson, a principal formulation scientist at Pfizer, details how platform formulations save time before commitment, shift risk downstream, and what AI tools need to earn trust.
|Articles|April 15, 2002
- BioPharm International-04-01-2002
- Volume 15
- Issue 4
Analytical Advances: Paperless or Less Paper?
Author(s)Mary Ellen Goffredo
by Mary Ellen Goffredo, NuGenesis Technologies Corporation Weighing the Options
Advertisement
Articles in this issue
over 24 years ago
Beyond QSITover 24 years ago
Determining Protein Concentration, Part 1: Methodologyover 24 years ago
Guest Editorial: The Protein Production Challengeover 24 years ago
Business Matters: Personalized Medicine or Blockbusterology?over 24 years ago
Advances in Amino Acid AnalysisAdvertisement
Related to this article
Advertisement
Advertisement
Trending on BioPharm International
1
Fresenius and WuXi Biologics Sign Exclusive Agreement Covering Up to 37 Biosimilar Candidates
2
Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma
3
Samsung Biologics Secures 97.66% of PolyPeptide Shares in Tender Offer
4
Resolving the Speed-Specificity Trade-Off in Biopharma High-Throughput Screening
5